Major Depressive Disorder

More than 260 million people worldwide are affected by major depressive disorder (MDD), which is characterized by a persistently depressed mood or loss of interest in daily activities that can impact normal daily functioning, relationships, and overall quality of life. Treatments range from selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and antidepressants. Along with behavioral therapy, these medications benefit between 40–70% of people suffering from depression. One third of patients do not benefit adequately from these treatments.

Clinical Trials: Major Depressive Disorder

Neurocrine Biosciences is currently conducting the SAVITRI™ study, a Phase 2 study to assess the efficacy and safety of NBI-1065845 in patients with major depressive disorder. For more information about this Phase 2 study of NBI-1065845, please visit studiesonmdd.com or  ClinicalTrials.gov.

Neurocrine Biosciences is initiating a Phase I clinical study with NBI-1070770, a novel, orally active small molecule with a mechanism of action that has already been validated clinically by parenterally administered molecules.